Kenneth Hoberman

Chief Operating Officer at STEMLINE THERAPEUTICS, INC.

Net worth: 12 M $ as of 2026-05-30

61 year

Health Technology

Consumer Services

Profile

Kenneth Hoberman is Vice Chairman at Lirum Therapeutics, Inc. since 2021.
Mr. Hoberman is Independent Director at TG Therapeutics, Inc. since 2014.
Mr. Hoberman is Independent Director at Nuvectis Pharma, Inc. since 2021.
Mr. Hoberman is Chief Operating Officer at Stemline Therapeutics, Inc. since 2013.
Mr. Hoberman was Vice President-Corporate & Business Development at Keryx Biopharmaceuticals, Inc. from 2004 to 2012.
Mr. Hoberman completed undergraduate studies at Boston University.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
TG THERAPEUTICS, INC. 0.18%	2026-06-10	279,653 ( 0.18% )	11 M $	2026-05-30
NUVECTIS PHARMA, INC. 0.63%	2026-06-10	168,140 ( 0.63% )	2 M $	2026-05-30

Kenneth Hoberman active positions

Companies	Position	Start
STEMLINE THERAPEUTICS, INC.	Chief Operating Officer	2012-12-31
TG THERAPEUTICS, INC.	Director/Board Member	2014-12-14
NUVECTIS PHARMA, INC.	Director/Board Member	2021-06-30
LIRUM THERAPEUTICS, INC.	Director/Board Member	2021-10-31

All active positions of Kenneth Hoberman

Former positions of Kenneth Hoberman

Companies	Position	End
KERYX BIOPHARMACEUTICALS	Corporate Officer/Principal	2011-12-31

See the detail of Kenneth Hoberman's experience

Training of Kenneth Hoberman

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Kenneth Hoberman's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	6
TG Therapeutics, Inc. TG Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company	Health Technology
Keryx Biopharmaceuticals, Inc. Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which focuses on therapies for patients with renal disease	Health Technology
Stemline Therapeutics, Inc. Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel oncology therapeutics	Health Technology
Boston University Boston University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops medicines for treatment of cancer	Health Technology
Lirum Therapeutics, Inc. Lirum Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that focuses on the treatment of debilitating diseases	Health Technology